Phase 1
Completed N=16
A Study of Glucagon Administered in Different Forms and Routes to Healthy Adults
Healthy
Source: ClinicalTrials.gov NCT02778113 ↗
Enrolled (actual)
16
Serious AEs
0.0%
Results posted
Sep 2019
Primary outcomePrimary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) — 0; 0; 0; 0 Participants
Summary
The main purpose of this study was to evaluate the safety and tolerability of nasal glucagon (NG). The study drug was delivered into the participant's nostril (intranasally) or was given as an injection just under the skin (subcutaneously) once in each of four study periods. The study lasted about 23 days for each participant.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With One or More Serious Adverse Event(s) (SAEs) |
0; 0; 0; 0 | — |
| SECONDARY Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to T (AUC[0-tlast]) of Baseline Adjusted Glucagon |
NA; 38.9; 293; 2060 | — |
| SECONDARY PK: Area Under the Curve Extrapolated to Infinity (AUC[0-inf]) of Baseline Adjusted Glucagon |
NA; 589; 2250 | — |
| SECONDARY PK: Time to Maximum Concentration (Tmax) of Baseline Adjusted Glucagon |
0.17; 0.25; 0.25; 0.33 | — |
| SECONDARY PK: Maximum Change From Baseline Concentration (Cmax) of Glucagon |
NA; 217; 1000; 3260 | — |
| SECONDARY Pharmacodynamics (PD): Area Under the Effect Concentration Time Curve (AUEC₀-₄) of Glucose |
-0.168; 0.0617; 0.566; 0.448 | — |
| SECONDARY PD: Time to Maximum Concentration (Tmax) of Baseline-Adjusted Glucose |
0.33; 0.36; 0.50; 0.37 | — |
| SECONDARY PD: Baseline-Adjusted Glucose Maximum Concentration (BGmax) |
0.811; 1.92; 3.20; 3.28 | — |
Eligibility Criteria
Inclusion Criteria
- Body mass index (BMI) greater than or equal to 20.00 and below or equal to 28.00 kg/m².
- Light-, non- or ex-smokers.
- Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on physical examination and/or clinical laboratory evaluations (hematology, biochemistry, ECG and urinalysis).
Exclusion Criteria
- Presence of any nose piercings.
- History of significant hypersensitivity to glucagon or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs.
- Presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects.
- Presence of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease.
- Presence of clinically significant findings on nasal examination and bilateral anterior rhinoscopy.
- Fasting blood glucose above 5.0 millimoles per liter (mmol/L) at screening, following a 12-hour fasting period.
- Fasting blood glucose assessed with a glucose meter above 5.5 mmol/L 0.5 hour before each dosing.
Data sourced from ClinicalTrials.gov (NCT02778113). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.